Sanofi vaccine for potentially fatal bacterial infection meets Phase II goals

Sanofi's (SNY) vaccine for the prevention of the Clostridium difficile (C. diff) infection (CDI) met its primary objectives in a Phase II trial.

The vaccine generated an immune response against C. diff toxins A and B, the ones that are largely responsible for CDI, which is a bacterial infection that can cause life-threatening gut inflammation and diarrhea.

The results put Sanofi ahead of Pfizer (PFE) and Valneva for preventing CDI.

Sanofi is now enrolling 15,000 participants in 17 countries for a Phase III trial.

Over 336,000 Americans a year become infected with C. difficile, and the infection is becoming ever more prevalent in healthcare facilities, partly due to the overuse of antibiotics. (PR)

From other sites
Comments (1)
  • Investing Doc
    , contributor
    Comments (1038) | Send Message
    The costs associated with C.Diff are enormous. Besides the obvious morbidity and mortality costs, which are considerable, CDAD cases incur longer hospitalizations, cause additional nursing work burden (moving patients to isolation rooms, for example), and worsen outcomes for primary diagnoses. If successful (admittedly a mighty big if) the potential market and uptake for this vaccine would be huge.
    19 May 2014, 11:46 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs